Icosavax

Icosavax, Inc. engages in the development and commercialization of vaccines against infectious diseases. It focuses on developing vaccine candidates for viral causes of pneumonia in older adults. The company was founded by Neil King and David Baker on November 1, 2017 and is headquartered in Seattle, WA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Icosavax is a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases.

NEW ORLEANS , Jan. 26, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

ICOSAVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Icosavax, Inc. (NASDAQ: ICVX) to AstraZeneca for $15.00 per share in cash plus a non-tradable contingent value right to receive up to $5.00 in cash, payable upon achievement of specified regulatory and net sales milestones, is fair to Icosavax shareholders. The tender offer in connection with the proposed transaction is currently set to expire on or around January 26, 2024. Halper Sade.

ICVX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Icosavax, Inc. Is Fair to Shareholders

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Icosavax, Inc. (NasdaqGS: ICVX) to AstraZeneca. Under the terms of the proposed transaction, shareholders of Icosavax will receive $15.00 in cash at closing, plus a non-tradable contingent value right to receive up to $5.00 in cash, payable upon achievement of specified regulatory and net sales milestones, for.

ICOSAVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX

Does Icosavax, Inc. (ICVX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Icosavax, Inc. (ICVX) Is Up 0.10% in One Week: What You Should Know

Icosavax, Inc. (ICVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Icosavax, Inc. (ICVX) Moves to Buy: Rationale Behind the Upgrade

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Icosavax, Inc. (NASDAQ: ICVX) breached their fiduciary duties in connection with the proposed sale of the Company to AstraZeneca. You can click or copy and paste the following link to join this investigation: https://www.johnsonfistel.com/investigations/Icosavax-co On November 30, 2023, Icosavax announced that it had entered a deal to merge with AstraZeneca.

SHAREHOLDER NEWS: Johnson Fistel Investigates Proposed Sale of Icosavax; Is the Deal in the Best Interest of Shareholders?

AstraZeneca

Shares of Icosavax (ICVX) skyrocketed over 48% in early trading Tuesday after AstraZeneca (AZN) agreed to purchase the biopharma company for $1.1 billion to expand its reach into cutting-edge vaccine technology.

Why AstraZeneca Is Buying Icosavax For $1.1 Billion

MILWAUKEE , Dec. 12, 2023 /PRNewswire/ -- Ademi LLP is investigating Icosavax (Nasdaq: ICVX) for possible breaches of fiduciary duty and other violations of law in its transaction with AstraZeneca. Click here to learn how to join the https://www.ademilaw.com/case/icosavax-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Icosavax, Inc. has obtained a Fair Price in its transaction with AstraZeneca

Seattle-based Icosavax, a spin-out from the University of Washington's Institute for Protein Design, will be acquired by biotech giant AstraZeneca for up to $1.

AstraZeneca will pay up to $1.1B to acquire Icosavax, a Univ. of Washington biotech spinout

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Icosavax, Inc. (NASDAQ: ICVX) to AstraZeneca for $15.00 per share in cash plus a non-tradable contingent value right to receive up to $5.00 in cash, payable upon achievement of specified regulatory and net sales milestones, is fair to Icosavax shareholders. Halper Sadeh encourages Icosavax shareholders to click here to learn more about their legal rights and options or contact Daniel S.

ICVX STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Icosavax, Inc. Is Fair to Shareholders

Icosavax (NASDAQ: ICVX ) stock is rising higher on Tuesday after announcing a major acquisition deal with AstraZeneca (NASDAQ: AZN ). According to a press release, AstraZeneca is acquiring Icosavax for $15 per share.

Why Is Icosavax (ICVX) Stock Up 46% Today?

Vaccines specialist Icosavax Inc (NASDAQ: ICVX) is set to surge 45% on Tuesday after agreeing to be taken over by Anglo-Swedish pharma group AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) for $838 million cash up front, potentially rising to $1.1 billion.  Having closed at $10.51 yesterday, the stock jumped to $15.25 in pre-market trading this morning, above the offer price of $15.00 per share.

Icosavax surges 45% in pre-market trading as AstraZeneca agrees takeover

AstraZeneca agreed to acquire respiratory vaccine developer Icosavax in a cash deal expected to close in the first quarter of next year.

This Vaccine Stock Soars 46% After $1.1 Billion AstraZeneca Deal

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc. (NASDAQ: ICVX), a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. The proposed acquisition will build on AstraZeneca's expertise in respiratory syncytial virus (RSV), strengthening AstraZeneca's Vaccines & Immune Therapies late-stage pipeline with Icosa.

AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data

AstraZeneca has agreed to acquire U.S.-based vaccine developer Icosavax for $1.1 billion, the companies announced Tuesday, to gain access to experimental vaccines targeting common respiratory disease-causing viruses.

AstraZeneca Will Acquire RSV Vaccine Developer Icosavax For $1.1 Billion

AstraZeneca has bought US biopharmaceutical company, Icosavax Inc, for up to $1.1 billion.  The Anglo-Swedish drugs maker said the deal will build on its expertise in respiratory syncytial virus (RSV), and strengthen its Vaccines & Immune Therapies late-stage pipeline with Icosavax's lead investigational vaccine candidate, IVX-A12.

AstraZeneca boosts RSV profile with $1.1bn Icosavax deal

Drugmaker AstraZeneca on Tuesday agreed to buy vaccine developer Icosavax in a deal valued at up to $1.1 billion to bolster its respiratory syncytial virus (RSV) vaccine portfolio.

AstraZeneca to buy RSV vaccine maker Icosavax for $1.1 bln

- Icosavax stockholders to receive $15.00 per share in cash at closing plus non-tradeable contingent value right (CVR) of up to $5.00 per share - - Representing a total equity value of up to $1.1 billion including the CVR - SEATTLE, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX) today announced it has entered into a definitive agreement pursuant to which AstraZeneca, through an acquisition subsidiary, will initiate a tender offer to acquire all of Icosavax's outstanding shares for a price of $15.00 per share in cash at closing, plus a non-tradable contingent value right to receive up to $5.00 in cash, payable upon achievement of specified regulatory and net sales milestones. The upfront cash portion of the consideration represents an equity value of approximately $838 million and a 43% premium over Icosavax's closing market price on December 11, 2023, and a 73% premium to Icosavax's volume-weighted average price for the preceding 60 trading days.

Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca

– IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV, and was generally well tolerated, consistent with prior IVX-A12 Phase 1 data – SEATTLE, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced positive topline interim results from its Phase 2 clinical trial of IVX-A12 against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults. “We're delighted to announce positive topline interim data from our Phase 2 trial of IVX-A12, our potential first-in-class combination vaccine candidate against RSV and hMPV,” said Adam Simpson, Chief Executive Officer of Icosavax.

Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults

The average of price targets set by Wall Street analysts indicates a potential upside of 175.9% in Icosavax, Inc. (ICVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Icosavax, Inc. (ICVX) Could Rally 175.87%: Here's is How to Trade

Icosavax, Inc. (ICVX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Icosavax, Inc. (ICVX) is on the Move, Here's Why the Trend Could be Sustainable

- Reported positive twelve-month durability data and initial proof-of-concept for revaccination with IVX-121 against RSV -

Icosavax Reports Third Quarter 2023 Financial Results and Provides Corporate Update

SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in and host one-on-one meetings at the Jefferies London Healthcare Conference, taking place from November 14-16, 2023 in London, UK.

Icosavax to Participate in the Jefferies London Healthcare Conference

SEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in and host one-on-one meetings at the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference, taking place from November 6-7, 2023 in New York City.

Icosavax to Participate in the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference

SEATTLE, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in the Cantor Fitzgerald Global Healthcare Conference 2023, taking place from September 26-28, 2023 in New York City.

News for Icosavax Stock (ICVX)